SEOM clinical guideline for treatment of kidney cancer (2017)
Clin. transl. oncol. (Print)
; 20(1): 47-56, ene. 2018. tab
Artigo
em Inglês
| IBECS
| ID: ibc-170467
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge (AU)
RESUMEN
No disponible
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Carcinoma de Células Renais
/
Neoplasias Renais
Tipo de estudo:
Ensaio clínico controlado
/
Estudo de etiologia
/
Guia de prática clínica
/
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
Clinica Universidad de Navarra/Spain
/
Hospital Clínico/Spain
/
Hospital Universitari Mutua Terrassa/Spain
/
Hospital Universitario 12 de Octubre/Spain
/
Hospital Universitario Ramón y Cajal/Spain
/
Hospital Universitario Son Espases/Spain
/
Institut Catala dOncologia/Spain
/
Parc Taulí Hospital Universitari/Spain
/
Reina Sofía Hospital/Spain
/
Vall dHebron University Hospital and Institute of Oncology/Spain